Long-term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials

Fred Poordad, Rui Sarmento E. Castro, Armen Asatryan, Humberto Aguilar, Patrice Cacoub, Douglas Dieterich, Rui Tato Marinho, Armando Carvalho, Asma Siddique, Yiran Bonnie Hu, Mariem Charafeddine, Mark Bondin, Nader Khan, Daniel E. Cohen, Franco Felizarta

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials'. Together they form a unique fingerprint.

Medicine & Life Sciences